Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1590-3478
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis ; volume:42 ; number:8 ; day:20 ; month:5 ; year:2021 ; pages:3135-3143 ; date:8.2021
Neurological sciences ; 42, Heft 8 (20.5.2021), 3135-3143, 8.2021
- Urheber
-
Negida, Ahmed
Ghaith, Hazem S.
Fala, Salma Yousry
Ahmed, Hussien
Bahbah, Eshak I.
Ebada, Mahmoud Ahmed
Aziz, Mohamed Abd Elalem
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10072-021-05319-7
- URN
-
urn:nbn:de:101:1-2021103011102581272859
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Negida, Ahmed
- Ghaith, Hazem S.
- Fala, Salma Yousry
- Ahmed, Hussien
- Bahbah, Eshak I.
- Ebada, Mahmoud Ahmed
- Aziz, Mohamed Abd Elalem
- SpringerLink (Online service)
Ähnliche Objekte (12)
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis